Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker ABBV · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Oct 23, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Labeling | BLA761262 ↗ Letter or label ↗ |
| Oct 23, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Efficacy | BLA761105 ↗ Letter or label ↗ |
| Oct 14, 2026 | CANASA MESALAMINE | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA021252 ↗ |
| Sep 29, 2026 | Natrelle Silicone-Filled Breast Implants and Natrelle INSPI… Prosthesis, breast, noninflatable, internal, silicone gel-f… | ABBV Allergan | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P020056 ↗ |
| Sep 25, 2026 | JUVMO TAVAPADON | ABBV Abbvie | New drug (NDA) Type 1 - New Molecular Entity | NDA220415 ↗ |
| Sep 11, 2026 | KYBELLA DEOXYCHOLIC ACID | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA206333 ↗ Letter or label ↗ |
| Sep 11, 2026 | KYBELLA DEOXYCHOLIC ACID | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA206333 ↗ Letter or label ↗ |
| Aug 11, 2026 | Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, Skin… Implant, dermal, for aesthetic use | ABBV Allergan | Device approval (PMA), supplement Normal 180 Day Track | P110033 ↗ |
| Aug 11, 2026 | Ultra, Ultra XC, Ultra Plus XC Implant, dermal, for aesthetic use | ABBV Allergan | Device approval (PMA), supplement Normal 180 Day Track | P050047 ↗ |
| Jul 23, 2026 | NORVIR RITONAVIR | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA209512 ↗ |
| Jul 23, 2026 | NORVIR RITONAVIR | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA022417 ↗ |
| Jul 23, 2026 | KALETRA LOPINAVIR; RITONAVIR | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA021906 ↗ |
| Jul 23, 2026 | KALETRA LOPINAVIR; RITONAVIR | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA021251 ↗ |
| Jun 30, 2026 | RINVOQ UPADACITINIB | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA218347 ↗ |
| Jun 30, 2026 | RINVOQ UPADACITINIB | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA211675 ↗ |
| Jun 26, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Labeling | BLA761262 ↗ |
| Jun 26, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Efficacy | BLA761105 ↗ |
| Jun 12, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Labeling | BLA761262 ↗ |
| Jun 12, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Efficacy | BLA761105 ↗ |
| Jun 11, 2026 | SKINVIVE by JUVEDERM® Implant, dermal, for aesthetic use | ABBV Allergan | Device approval (PMA), supplement Panel Track | P110033 ↗ |
| May 27, 2026 | DECNUPAZ PIVEKIMAB SUNIRINE-PVZY | ABBV Abbvie Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761460 ↗ |
| May 21, 2026 | LINZESS LINACLOTIDE | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA202811 ↗ |
| May 20, 2026 | VENCLEXTA VENETOCLAX | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA208573 ↗ |
| May 6, 2026 | LUPRON LEUPROLIDE ACETATE | ABBV Abbvie Endocrine Inc | New drug (NDA), supplement Labeling | NDA019010 ↗ |
| Mar 31, 2026 | DEPAKOTE ER DIVALPROEX SODIUM | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA021168 ↗ Letter or label ↗ |
| Mar 31, 2026 | DEPAKOTE SPRINKLES DIVALPROEX SODIUM | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA019680 ↗ Letter or label ↗ |
| Mar 31, 2026 | DEPAKOTE DIVALPROEX SODIUM | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA018723 ↗ Letter or label ↗ |
| Mar 19, 2026 | VYALEV FOSCARBIDOPA; FOSLEVODOPA | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA216962 ↗ |
| Mar 19, 2026 | DUOPA CARBIDOPA; LEVODOPA | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA203952 ↗ |
| Mar 18, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Labeling | BLA761262 ↗ |
| Mar 18, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Labeling | BLA761105 ↗ |
| Mar 17, 2026 | COMBIGAN BRIMONIDINE TARTRATE; TIMOLOL MALEATE | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA021398 ↗ |
| Mar 11, 2026 | OZURDEX DEXAMETHASONE | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA022315 ↗ |
| Mar 6, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Labeling | BLA761262 ↗ |
| Mar 6, 2026 | SKYRIZI RISANKIZUMAB-RZAA | ABBV Abbvie Inc | Biologic (BLA), supplement Efficacy | BLA761105 ↗ |
| Feb 19, 2026 | VENCLEXTA VENETOCLAX | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA208573 ↗ |
| Jan 16, 2026 | Natrelle 133S Tissue Expanders | ABBV AbbVie | Device clearance (510(k)) Special | K254126 ↗ |
| Dec 23, 2025 | HUMIRA ADALIMUMAB | ABBV Abbvie Inc | Biologic (BLA), supplement Labeling | BLA125057 ↗ |
| Dec 18, 2025 | VRAYLAR CARIPRAZINE HYDROCHLORIDE | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA204370 ↗ |
| Dec 18, 2025 | VRAYLAR CARIPRAZINE HYDROCHLORIDE | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA204370 ↗ |
| Dec 18, 2025 | VRAYLAR CARIPRAZINE HYDROCHLORIDE | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA204370 ↗ |
| Dec 18, 2025 | VRAYLAR CARIPRAZINE HYDROCHLORIDE | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA204370 ↗ |
| Dec 17, 2025 | ORIAHNN ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX S… | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA213388 ↗ |
| Dec 17, 2025 | ORILISSA ELAGOLIX SODIUM | ABBV Abbvie | New drug (NDA), supplement Labeling | NDA210450 ↗ |
| Nov 25, 2025 | PRED MILD PREDNISOLONE ACETATE | ABBV Abbvie | New drug (NDA), supplement Manufacturing (CMC) | NDA017100 ↗ |
| Nov 14, 2025 | LUPRON DEPOT-PED LEUPROLIDE ACETATE | ABBV Abbvie Endocrine Inc | New drug (NDA), supplement Labeling | NDA020263 ↗ |
| Nov 4, 2025 | LINZESS LINACLOTIDE | ABBV Abbvie | New drug (NDA), supplement Efficacy | NDA202811 ↗ |
| Oct 21, 2025 | IMBRUVICA IBRUTINIB | ABBV Pharmacyclics LLC | New drug (NDA), supplement Labeling | NDA217003 ↗ |
| Oct 21, 2025 | IMBRUVICA IBRUTINIB | ABBV Pharmacyclics LLC | New drug (NDA), supplement Labeling | NDA210563 ↗ |
| Oct 21, 2025 | IMBRUVICA IBRUTINIB | ABBV Pharmacyclics LLC | New drug (NDA), supplement Labeling | NDA205552 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:15 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates